Should I buy or sell Revolution Medicines stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVMD shares. View RVMD analyst ratings or view top-rated stocks .

What is Revolution Medicines' stock price target for 2024?

10 brokerages have issued 12 month price targets for Revolution Medicines' stock. Their RVMD share price targets range from $28.00 to $48.00. On average, they expect the company's stock price to reach $41.20 in the next year. This suggests a possible upside of 18.0% from the stock's current price. View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts .

How have RVMD shares performed in 2024?

Revolution Medicines' stock was trading at $28.68 at the beginning of the year. Since then, RVMD stock has increased by 21.8% and is now trading at $34.92. View the best growth stocks for 2024 here .

Are investors shorting Revolution Medicines?

Revolution Medicines saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 12,000,000 shares, a decrease of 26.8% from the March 15th total of 16,400,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 8.9 days. View Revolution Medicines' Short Interest .

When is Revolution Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our RVMD earnings forecast .

How were Revolution Medicines' earnings last quarter?

Revolution Medicines, Inc. (NASDAQ:RVMD) issued its earnings results on Monday, February, 26th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.29. The business earned $0.74 million during the quarter, compared to analysts' expectations of $1.20 million. Revolution Medicines's quarterly revenue was down 95.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.63) earnings per share.

What ETFs hold Revolution Medicines' stock?

ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , Range Cancer Therapeutics ETF (CNCR) , Loncar China Biopharma ETF (CHNA) , Principal Healthcare Innovators ETF (BTEC) , SPDR S&P Biotech ETF (XBI) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Health Care ETF (MEDI) .

What other stocks do shareholders of Revolution Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC) , Editas Medicine (EDIT) , Homology Medicines (FIXX) , Gossamer Bio (GOSS) , Livongo Health (LVGO) , Sorrento Therapeutics (SRNE) , Black Diamond Therapeutics (BDTX) , Beam Therapeutics (BEAM) , CrowdStrike (CRWD) and Precision BioSciences (DTIL) .

When did Revolution Medicines IPO?

Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Revolution Medicines' major shareholders?

Revolution Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.21%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Anthony W Boor, Barbara Weber , Jack Anders , Jeanna Steele, Jeff Cislini , Lorence H Kim , Margaret A Horn , Mark A Goldsmith , Peter Svennilson , Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey , Sushil Patel, Thilo Schroeder and Xiaolin Wang . View institutional ownership trends .

How do I buy shares of Revolution Medicines?

Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Top-Rated StocksTop-Rated

NASDAQ:RVMD

Revolution Medicines (RVMD) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free RVMD Stock Alerts

$34.92

-0.91 (-2.54%)

(As of 04/19/2024 ET)

Compare

Today's Range: $34.23
▼
$36.37
50-Day Range: $29.00
▼
$37.41
52-Week Range: $15.44
▼
$38.73

Volume: 1.24 million shs
Average Volume: 1.39 million shs
Market Capitalization: $5.75 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.20

Get Revolution Medicines alerts:

Revolution Medicines MarketRank™ Stock Analysis

Analyst Rating: Buy
3.10 Rating Score
Upside/Downside: 18.0% Upside
$41.20 Price Target
Short Interest: Healthy
7.29% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: 0.41
Based on 9 Articles This Week
Insider Trading: Selling Shares
$671,249 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.18) to ($3.40) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.18 out of 5 stars

Medical Sector

139th out of 911 stocks

Biological Products, Except Diagnostic Industry

15th out of 150 stocks

3.6

Analyst's Opinion

Consensus Rating
Revolution Medicines has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Revolution Medicines has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
7.29% of the outstanding shares of Revolution Medicines have been sold short.
Short Interest Ratio / Days to Cover
Revolution Medicines has a short interest ratio ("days to cover") of 8.9.
Change versus previous month
Short interest in Revolution Medicines has recently decreased by 26.83%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Revolution Medicines does not currently pay a dividend.
Dividend Growth
Revolution Medicines does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Revolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Revolution Medicines is -0.81.

3.0

News and Social Media Coverage

News Sentiment
Revolution Medicines has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Revolution Medicines this week, compared to 3 articles on an average week.
Search Interest
10 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.
MarketBeat Follows
7 people have added Revolution Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $671,249.00 in company stock.
Percentage Held by Insiders
Only 8.50% of the stock of Revolution Medicines is held by insiders.
Percentage Held by Institutions
94.34% of the stock of Revolution Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Revolution Medicines are expected to decrease in the coming year, from ($3.18) to ($3.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revolution Medicines is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revolution Medicines is -9.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Revolution Medicines has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

Click here to get them (for Free).

About Revolution Medicines Stock (NASDAQ:RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RVMD Stock News Headlines

April 13, 2024 | insidertrades.com

Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) Director Sells 2,155 Shares of Stock

March 29, 2024 | insidertrades.com

Insider Selling: Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Sells 1,500 Shares of Stock

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

March 21, 2024 | insidertrades.com

Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,252 Shares

April 17, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - RVMD

April 17, 2024 | msn.com

Revolution Medicines (RVMD) Price Target Increased by 5.15% to 41.65

April 15, 2024 | investing.com

Revolution Medicines executive sells over $619k in company stock

April 14, 2024 | investing.com

Revolution Medicines director sells shares worth $79,735

April 19, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

April 14, 2024 | americanbankingnews.com

Sushil Patel Sells 2,155 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

April 14, 2024 | americanbankingnews.com

Mark A. Goldsmith Sells 7,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD) Stock

April 14, 2024 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Price Target Raised to $45.00 at Oppenheimer

April 12, 2024 | markets.businessinsider.com

Buy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer Therapies

April 12, 2024 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Shares Gap Up to $32.99

April 11, 2024 | uk.investing.com

Revolution Medicines reports progress in RAS cancer therapy

April 11, 2024 | americanbankingnews.com

Raymond James Upgrades Revolution Medicines (NASDAQ:RVMD) to Strong-Buy

April 10, 2024 | msn.com

What's Going On With Revolution Medicines Stock?

April 10, 2024 | americanbankingnews.com

Outlook Therapeutics (NASDAQ:OTLK) versus Revolution Medicines (NASDAQ:RVMD) Head to Head Comparison

April 10, 2024 | uk.investing.com

Revolution Medicines reports breakthrough in RAS-mutant cancer treatment

April 9, 2024 | globenewswire.com

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 9, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates Buy Rating for Revolution Medicines (NASDAQ:RVMD)

April 8, 2024 | markets.businessinsider.com

Revolution Medicines’ Robust Cancer Drug Pipeline Justifies Buy Rating

April 8, 2024 | globenewswire.com

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

April 4, 2024 | globenewswire.com

Revolution Medicines to Participate in Upcoming Investor Conferences

March 28, 2024 | globenewswire.com

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

March 22, 2024 | investing.com

Revolution Medicines executive sells over $67,000 in stock

March 22, 2024 | investing.com

Revolution Medicines general counsel sells $39,542 in stock

See More Headlines

Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:RVMD
CUSIP: N/A
CIK: 1628171
Web: www.revmed.com
Phone: 650-481-6801
Fax: N/A
Employees: 378
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $41.20
High Stock Price Target: $48.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +18.3%
Consensus Rating: Buy
Rating Score (0-4): 3.10
Research Coverage: 10 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-436,370,000.00
Net Margins: N/A
Pretax Margin: -3,798.71%
Return on Equity: -38.39%
Return on Assets: -33.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.06
Quick Ratio: 13.06

Sales & Book Value

Annual Sales: $11.58 million
Price / Sales: 495.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.09 per share
Price / Book: 3.14

Miscellaneous

Outstanding Shares: 164,690,000
Free Float: 150,691,000
Market Cap: $5.74 billion
Optionable: Optionable
Beta: 1.54

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Mark A. Goldsmith Ph.D. (Age 62)
CEO, President & Chairman
Comp: $1.05M
Mr. Jack Anders (Age 47)
Chief Financial Officer
Comp: $544.8k
Ms. Margaret A. Horn J.D. (Age 61)
Chief Operating Officer
Comp: $775.6k
Dr. Stephen M. Kelsey FRC Path. (Age 63)
FRCP, M.D., President of Research & Development
Comp: $779k
Ms. Xiaolin Wang (Age 53)
Executive Vice President of Clinical Development
Comp: $604.1k
Dr. Martin D. Burke M.D.
Ph.D., Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael A. Fischbach Ph.D. (Age 43)
Academic Co-Founder & Member of Scientific Advisory Board
Dr. Kevan M. Shokat Ph.D.
Academic Co-Founder & Member of Scientific Advisory Board
Mr. Walter Reiher Ph.D.
Chief Information Officer
Ms. Jan Smith Ph.D.
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?: 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" RVMD shares.
View RVMD analyst ratings or view top-rated stocks.
What is Revolution Medicines' stock price target for 2024?: 10 brokerages have issued 12 month price targets for Revolution Medicines' stock. Their RVMD share price targets range from $28.00 to $48.00. On average, they expect the company's stock price to reach $41.20 in the next year. This suggests a possible upside of 18.0% from the stock's current price.
View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts.
How have RVMD shares performed in 2024?: Revolution Medicines' stock was trading at $28.68 at the beginning of the year. Since then, RVMD stock has increased by 21.8% and is now trading at $34.92.
View the best growth stocks for 2024 here.
Are investors shorting Revolution Medicines?: Revolution Medicines saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 12,000,000 shares, a decrease of 26.8% from the March 15th total of 16,400,000 shares. Based on an average trading volume of 1,350,000 shares, the short-interest ratio is presently 8.9 days.
View Revolution Medicines' Short Interest.
When is Revolution Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our RVMD earnings forecast.
How were Revolution Medicines' earnings last quarter?: Revolution Medicines, Inc. (NASDAQ:RVMD) issued its earnings results on Monday, February, 26th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.85) by $0.29. The business earned $0.74 million during the quarter, compared to analysts' expectations of $1.20 million. Revolution Medicines's quarterly revenue was down 95.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.63) earnings per share.

What ETFs hold Revolution Medicines' stock?: ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Health Care ETF (MEDI).
What other stocks do shareholders of Revolution Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).
When did Revolution Medicines IPO?: Revolution Medicines (RVMD) raised $150 million in an initial public offering on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.
Who are Revolution Medicines' major shareholders?: Revolution Medicines' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Mass General Brigham Inc (0.21%) and Allspring Global Investments Holdings LLC (0.00%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Sushil Patel, Thilo Schroeder and Xiaolin Wang.
View institutional ownership trends.
How do I buy shares of Revolution Medicines?: Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Revolution Medicines (RVMD) Stock Price, News & Analysis

Revolution Medicines MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Revolution Medicines Stock (NASDAQ:RVMD)

RVMD Stock Price History

RVMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RVMD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™